Literature DB >> 24726205

Heparin-induced thrombocytopenia in the critically ill: interpreting the 4Ts test in a randomized trial.

Mark Crowther1, Deborah Cook2, Gordon Guyatt1, Nicole Zytaruk1, Ellen McDonald1, David Williamson1, Martin Albert1, Peter Dodek1, Simon Finfer1, Shirley Vallance1, Diane Heels-Ansdell1, Lauralyn McIntyre1, Sangeeta Mehta1, Francois Lamontagne1, John Muscedere1, Michael Jacka1, Olivier Lesur1, Jim Kutsiogiannis1, Jan Friedrich1, James R Klinger1, Ismael Qushmaq1, Lisa Burry1, Kosar Khwaja1, Jo-Ann Sheppard1, Theodore E Warkentin1.   

Abstract

BACKGROUND: Thrombocytopenia occurs in 20% to 45% of critically ill medical-surgical patients. The 4Ts heparin-induced thrombocytopenia (HIT) score (with 4 domains: Thrombocytopenia, Timing of thrombocytopenia, Thrombosis and oTher reason[s] for thrombocytopenia) might reliably identify patients at low risk for HIT. Interobserver agreement on 4Ts scoring is uncertain in this setting.
OBJECTIVE: To evaluate whether a published clinical prediction rule (the "4Ts score") reliably rules out HIT in "low-risk" intensive care unit (ICU) patients as assessed by research coordinators (who prospectively scored) and 2 adjudicators (who scored retrospectively) during an international heparin thromboprophylaxis trial (PROTECT, NCT00182143).
METHODS: Of 3746 medical-surgical ICU patients in PROTECT, 794 met the enrollment criteria for this HIT substudy. Enrollment was predicated on one of the following occurring in ICU: platelets less than 50×10(9)/L, platelets decreased to 50% of ICU admission value (if admission value<100×10(9)/L), any venous thrombosis, or if HIT was otherwise clinically suspected. Independently, 4Ts scores were completed in real time by research coordinators blinded to study drug and laboratory HIT results, and retrospectively by 2 adjudicators blinded to study drug, laboratory HIT results, and research coordinators' scores; the adjudicators arrived at consensus in all cases. Of the 763 patients, 474 had a central or local laboratory HIT test performed and had 4Ts scoring by adjudicators; 432 were scored by trained research coordinators. Heparin-induced thrombocytopenia was defined by a centrally performed positive serotonin release assay (SRA).
RESULTS: Of the 474 patients with central adjudication, 407 (85.9%) had a 4Ts score of 3 or lower, conferring a low pretest probability (PTP) of HIT; of these, 6 (1.5% [95% confidence interval, 0.7%-3.2%) had a positive SRA. Fifty-nine (12.4%) had a moderate PTP (4Ts score of 4-5); of these, 4 (6.8%) had a positive SRA. Eight patients had a high PTP (4Ts score of ≥6); of these, 1 (12.5%) had a positive SRA. Raw agreement between research coordinators and central adjudication on each domain of the 4Ts score and low, intermediate, and high PTP was good. However, chance-corrected agreement was variable between adjudicators (weighted κ values of 0.31-0.93) and between the adjudicator consensus and research coordinators (weighted κ values of 0.13 and 0.78). Post hoc review of the 6 SRA-positive cases with an adjudicated low PTP demonstrated that their scores would have been increased if the adjudicators had had additional information on heparin exposure prior to ICU admission. In general, the fourth domain of 4Ts (oTher causes of thrombocytopenia) generated the most disagreement.
CONCLUSIONS: Real-time 4Ts scoring by research coordinators at the time of testing for HIT was not consistent with 4Ts scores obtained by central adjudicators. The results of this comprehensive HIT testing highlight the need for further research to improve the assessment of PTP scoring of HIT for critically ill patients.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Critical care; Heparin-induced thrombocytopenia; Intensive care unit; Thrombocytopenia

Mesh:

Substances:

Year:  2014        PMID: 24726205     DOI: 10.1016/j.jcrc.2014.02.004

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  12 in total

1.  Developing a spinal cord injury research strategy using a structured process of evidence review and stakeholder dialogue. Part III: outcomes.

Authors:  J W Middleton; L Piccenna; R Lindsay Gruen; S Williams; G Creasey; S Dunlop; D Brown; P E Batchelor; D J Berlowitz; S Coates; J A Dunn; J B Furness; M P Galea; T Geraghty; B K Kwon; S Urquhart; D Yates; P Bragge
Journal:  Spinal Cord       Date:  2015-06-23       Impact factor: 2.772

2.  Heparin induced thrombocytopenia: position paper from the Italian Society on Thrombosis and Haemostasis (SISET).

Authors:  Rossella Marcucci; Martina Berteotti; Anna M Gori; Betti Giusti; Angela A Rogolino; Elena Sticchi; Agatina Alessandrello Liotta; Walter Ageno; Erica De Candia; Paolo Gresele; Marina Marchetti; Marco Marietta; Armando Tripodi
Journal:  Blood Transfus       Date:  2020-12-28       Impact factor: 3.443

3.  4Ts scoring with hemofiltration or hemodialysis clotting.

Authors:  Theodore E Warkentin
Journal:  J Clin Monit Comput       Date:  2015-02       Impact factor: 2.502

4.  Platelet response to direct thrombin inhibitor or fondaparinux treatment in patients with suspected heparin-induced thrombocytopenia.

Authors:  Tiffany K Pon; Anjlee Mahajan; Aaron Rosenberg; Alpesh Amin; Digish Shah; Ian Jenkins; Vineet Gupta; Heather Hofmann; Anthony Bejjani; Richard White
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

5.  Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia.

Authors:  Allyson M Pishko; Sara Fardin; Daniel S Lefler; Koosha Paydary; Rolando Vega; Gowthami M Arepally; Mark Crowther; Lawrence Rice; Douglas B Cines; Adam Cuker
Journal:  Blood Adv       Date:  2018-11-27

Review 6.  Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally
Journal:  Blood       Date:  2017-04-17       Impact factor: 22.113

Review 7.  Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.

Authors:  Daniela R Junqueira; Liliane M Zorzela; Edson Perini
Journal:  Cochrane Database Syst Rev       Date:  2017-04-21

8.  Characterization of hospitalized cardiovascular patients with suspected heparin-induced thrombocytopenia.

Authors:  Felicitas Stoll; Miriel Gödde; Albrecht Leo; Hugo A Katus; Oliver J Müller
Journal:  Clin Cardiol       Date:  2018-12-03       Impact factor: 2.882

9.  Prevalence and clinical implications of anti-PF4/heparin antibodies in intensive care patients: a prospective observational study.

Authors:  Sixten Selleng; Kathleen Selleng; Sigrun Friesecke; Matthias Gründling; Sven-Olaf Kuhn; Ricarda Raschke; Olivia J Heidecke; Carsten Hinz; Gregor Hron; Theodore E Warkentin; Andreas Greinacher
Journal:  J Thromb Thrombolysis       Date:  2015-01       Impact factor: 2.300

Review 10.  Heparin-induced thrombocytopenia (HIT): Identification and treatment pathways.

Authors:  Mahmoud Fathi
Journal:  Glob Cardiol Sci Pract       Date:  2018-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.